Cidara Therapeutics

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics has recently gained FDA approval for rezafungin and is now focused on advancing its Cloudbreak platform in oncology and infectious disease indications, which has great potential. Potential revenue from rezafungin, CDTX's partnership-based business model and track record, and the major advantages of Cloudbreak platform all point to major upside potential for CDTX. My recommendation is "Buy" rather than "Strong Buy" because the Cloudbreak platform is still at a very early stage; setbacks are more likely than not and dilution risk is high.

Buy Cidara Therapeutics For The Cloudbreak Platform

Dr. Davarpanah will lead Cidara's oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational Lead in Oncology at Genentech/Roche SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development.

Cidara Therapeutics Announces Appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development

Cidara Therapeutics is a biotech company with an approved antifungal drug, Rezzayo, but its sales are not enough to offset expenses. The company's pipeline includes antifungal and antiviral agents, with CD388 being the most advanced drug in development for influenza. Cidara is also exploring the use of its drug-Fc conjugates in cancer medicine, targeting CD73, but the project is still in preclinical stages.

Cidara Therapeutics: Leveraging Antifungals To Move Into Cancer Therapy

Cidara Therapeutics (CDTX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.19 per share a year ago.

Cidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2023 and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Cidara's U.S. Commercial Partner, Melinta Therapeutics, has Initiated Commercial Launch of REZZAYO™ EMA Regulatory Decision for Rezafungin Expected by Year End 2023 SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced an update on REZZAYO™ (rezafungin for injection) which was approved by the U.S. Food and Drug Administration (FDA) earlier this year. Earlier today, Cidara's U.S. partner, Melinta Therapeutics, announced the commercial launch of REZZAYO.

Cidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today provided an update on the status of its ongoing CD388 program for prevention of influenza A and B, which is the subject of an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. As part of a recent prioritization of its R&D business, Janssen has announced its intention to discontinue internal development of the majority of its infectious disease pipeline, including JNJ-0953 (CD388). However, at this time, Janssen has not informed Cidara of any intention to terminate the agreement between the two parties. Cidara continues to work in collaboration with Janssen to complete the Phase 1 (NCT05285137 and NCT05619536) and Phase 2a (NCT05523089) clinical trials and will be reimbursed for all ongoing development activities by Janssen as per the Janssen Collaboration Agreement.

Cidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, announced today it has joined the broad market Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution. The newly reconstituted Index will become effective after the U.S. equity market opens on Monday, June 26, 2023.

Cidara Therapeutics Added to Russell Microcap® Index

SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CD388, Cidara's novel drug-Fc conjugate (DFC) candidate. CD388 is being developed in collaboration with Janssen Pharmaceuticals for the prevention of influenza A and B infection in adults who are at high risk of severe influenza, including those for whom vaccines are either ineffective or contraindicated.

Cidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

SAN DIEGO, June 20, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting drug-Fc conjugate (DFC), as well as the development of its novel DFCs from Cidara's Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.

Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit

SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting DFC candidate, as well as the development of its novel drug-Fc conjugates (DFCs) from Cidara's Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023.

Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit

With their first product approval last quarter, Europe should follow suit. Their U.S. partner is experienced in commercializing antibiotics.

Buy Cidara Therapeutics For Data Readout And European Foothold

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to save lives and improve the standard of care for patients facing serious diseases, today reported financial results for the first quarter ended March 31, 2023 and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

– Oral presentations demonstrate positive preclinical data highlighting CD388's activity against influenza A and B – – Oral presentations demonstrate positive preclinical data highlighting CD388's activity against influenza A and B –

Cidara Therapeutics Presents New Preclinical Data on Novel Drug-Fc Conjugate CD388 at the 7th International Society for Influenza and Other Respiratory Virus Diseases Conference

– U.S. launch of REZZAYO by Melinta expected in mid-2023 – – Company eligible to receive up to an additional $47 million in milestones from multiple existing partnerships based on successful completion of activities planned over the next year –

Cidara Therapeutics Receives $20 Million Milestone Payment Following FDA Approval of REZZAYO™

Altimmune

Ardelyx

FaZe Holdings Inc

ImmunityBio

Inovio Pharmaceuticals

Olaplex Holdings

RLX Technology

Silvergate Capital Corp

Tupperware

10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy Now? 10 To Watch Under $5

SAN DIEGO, March 31, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, is scheduled to participate in the following upcoming investor conferences.

Cidara Therapeutics to Participate in Upcoming Investor Conferences

Penny stocks to watch before next week. The post 7 Top Penny Stocks Under $5; Time To Buy Now?

7 Top Penny Stocks Under $5; Time To Buy Now?

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -1,800% and 45.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates

Cidara Therapeutics (NASDAQ: CDTX ) stock is falling on Thursday despite the immunotherapy company getting positive news from the FDA. The big FDA news is the approval of rezafungin as a treatment for “candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options.

Why Is Cidara Therapeutics (CDTX) Stock Down 12% Today?

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today reported financial results for the three months and full year ended December 31, 2022 and provided an update on its corporate activities and product pipeline.

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

SAN DIEGO & PARSIPPANY, N.J.--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC today announced that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. REZZAYO is the first new treatment option approved for patients with candidemia and invasive candidiasis in over a decade.

Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

– REZZAYO is a novel, once-weekly, next-generation echinocandin indicated for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options –

Cidara Therapeutics and Melinta Therapeutics Announce FDA Approval of REZZAYO™ (rezafungin for injection) for the Treatment of Candidemia and Invasive Candidiasis

SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, presented preclinical data on a CD73-targeting drug-Fc conjugate (DFC) candidate, CBO-212, from the Company's Cloudbreak® platform, at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023.

Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress

SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced the closing of its previously announced concurrent but separate underwritten public offerings of 11,086,000 shares of its common stock, including the exercise in full by the underwriter of its option to purchase an additional 1,446,000 shares of common stock, and 286,000 shares of its Series X Convertible Preferred Stock (each share of which is initially convertible into 10 shares of common stock), for aggregate gross proceeds of approximately $19.5 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Cidara Therapeutics Announces Closing of Public Offerings of Common Stock and Preferred Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares in Public Offering of Common Stock

News for Cidara Therapeutics Stock (CDTX)